Comparison of the agonist- and antagonist-bound...
Potential pathogenic mechanisms of Lp(a). The a...
An antagonist of LPA receptors, BrP-LPA, activa...
Schematic representation of the mechanism by wh...
Anti-fibroblast activation protein/FAP antibody...
LPA receptor antagonist-1 | C30H26ClNO5S | CID ...
Figure 5 from Autotaxin and LPA1 and LPA5 Recep...
Compilation of fibroblast types across steady a...
Effect of the selective LPA1 and LPA3 receptor ...
Effect of LPA 3 antagonist (7) on platelet | Do...
ATX-LPA 1 signaling regulates renal fibroblast ...
(PDF) LPA1 antagonist-derived LNPs deliver A20 ...
LPA1 receptor selective antagonist Ki16425 inhi...
LPA2 antagonist 2 | LPA Receptor | TargetMol
The selective LPA1/LPA3 antagonist Ki16425 inhi...
Cytoskeletal effects of LPA are mediated throug...
Increasing LPP1 activity attenuates LPA-induced...
Lp(a) and CVD Risk: Essential Knowledge for Cli...
Ki16425 (LPA Receptor Antagonist) - Echelon Bio...
Structure of the LPA 2 antagonists C35, H2L5186...
LPA1 antagonist directs human macrophages towar...
LPA receptor antagonist-1 | LPA Receptor Antago...
S1P, LPA, and FBS stimulate retraction of fibro...
(PDF) LPA1 antagonist BMS-986020 changes collag...
The LPA 1/3 antagonist, Ki16425, reduces athero...
Lysophosphatidic acid (LPA) induces α-smooth mu...
An LPA receptor antagonist, Ki16425, does not a...
Figure 2 from Fibroblast Activation Protein–Tar...
LPA potentiates fibroblast migration toward PDG...
Effects of LPA receptor agonists and antagonist...